Publikationen in Zusammenarbeit mit Forschern von Centro de Investigación Biomédica en Red sobre Enfermedades Raras (15)

2022

  1. Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients

    Cancers, Vol. 14, Núm. 13

2021

  1. Minimal residual disease in multiple myeloma: Something old, something new

    Cancers, Vol. 13, Núm. 17

2020

  1. Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach

    OncoImmunology, Vol. 9, Núm. 1

  2. Pilot study on the role of circulating mirnas for the improvement of the predictive ability of the 2mace score in patients with atrial fibrillation

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-11

  3. The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant

    Frontiers in Genetics, Vol. 11

2019

  1. MicroRNAs as potential regulators of platelet function and bleeding diatheses

    Platelets, Vol. 30, Núm. 7, pp. 803-808

2018

  1. An early increase of CD56 bright natural killer subset as dominant effect and predictor of response to extracorporeal photopheresis for graft-versus-host disease

    Transfusion, Vol. 58, Núm. 12, pp. 2924-2932

  2. microRNAs in the haemostatic system: More than witnesses of thromboembolic diseases?

    Thrombosis Research, Vol. 166, pp. 1-9

2017

  1. Defects of splicing in antithrombin deficiency

    Research and Practice in Thrombosis and Haemostasis, Vol. 1, Núm. 2, pp. 216-222

  2. Down regulation of the Munc18b-syntaxin-11 complex and β1-tubulin impairs secretion and spreading in neonatal platelets

    Thrombosis and Haemostasis, Vol. 117, Núm. 11, pp. 2079-2091

  3. High levels of latent antithrombin in plasma from patients with antithrombin deficiency

    Thrombosis and Haemostasis, Vol. 117, Núm. 5, pp. 880-888

  4. Transient desialylation in combination with a novel antithrombin deficiency causing a severe and recurrent thrombosis despite anticoagulation therapy

    Scientific Reports, Vol. 7

2016

  1. Heparanase activates antithrombin through the binding to its heparin binding site

    PLoS ONE, Vol. 11, Núm. 6

  2. Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction

    Blood, Vol. 128, Núm. 9, pp. 1282-1289

2010

  1. L718P mutation in the membrane-proximal cytoplasmic tail of β3 promotes abnormal αIIbβ3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype

    Haematologica, Vol. 95, Núm. 7, pp. 1158-1166